This has created a classical investment horizon mismatch or...

This has created a classical investment horizon mismatch or information asymmetry between impatient shareholders and management, impatient Shareholders might be pushing for results, but management can't disclose information unless it's confirmed and the promise of gold pot at the horizon has created this bad blood its unbearable, people have seen the past movement and seen the potential, I guess my suggestion to retails who invest in clinical stage biotech, stay away, dont invest in greed and get disappointed, there is no instant gratification, its a pain and its like thousand cuts either you die out of it or it may heal with scars, there was a moment when you had invested you would had become a millionaire, but that has passed, it will take sometime before this moves in that direction, I am not sure tomorrow is good news or bad news disguised as potential news or just shoring up retails.. just quit while you can if you are impatient..